A Japanese post-marketing surveillance of cetuximab (Erbituxw®) in patients with metastatic colorectal cancer

Japanese Journal of Clinical Oncology

Volumn 42, Issue 4, 2012, Pages 287-294

  Ishiguro, Megumi ^a   Watanabe, Toshiaki ^a,b   Yamaguchi, Kensei ^a,c   Satoh, Taroh ^a,d,e,f   Ito, Hideyuki ^g   Seriu, Taku ^a   Sakata, Yuh ^a,h   Sugihara, Kenichi ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b TEIKYO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c Department of Gastroenterology   (Japan)

^d Department of Medical Oncology ^*  (Japan)

^e University School of Medicine   (Japan)

^f OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^g Merck Serono Co   (Japan)

^h Department of Internal Medicine   (Japan)

Author keywords

Cetuximab; Colorectal cancer; Post marketing surveillance

Indexed keywords

CETUXIMAB;

ACNE; ADULT; AGED; ARTICLE; CARDIOTOXICITY; COLORECTAL CANCER; CORONARY SPASTIC ANGINA; DERMATITIS; DIARRHEA; DRUG ERUPTION; DRUG SAFETY; DRY SKIN; EMBOLISM; EYE DISEASE; FEMALE; GASTROINTESTINAL DISEASE; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERKALEMIA; HYPOCALCEMIA; HYPOCHLOREMIA; HYPOKALEMIA; HYPOMAGNESEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; INCIDENCE; INFUSION REACTION; INTERSTITIAL LUNG DISEASE; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; METASTATIC COLORECTAL CANCER; MULTICENTER STUDY; NEUTROPENIA; PARONYCHIA; POSTMARKETING SURVEILLANCE; SKIN DISEASE; THROMBOSIS; TREATMENT DURATION; WOUND HEALING IMPAIRMENT;

AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; COLORECTAL NEOPLASMS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PRODUCT SURVEILLANCE, POSTMARKETING;

EID: 84859300222     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hys005     Document Type: Article

References (17)

1. Ciardiello F, Tortora G. EGFR antagonists in cancer treatment. N Engl J Med 2008;358:1160-74.
2. Ciardiello F, Tortora G. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin Cancer Res 2001;7:2958-70.
3. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004;351:337-45.
4. Jonker DJ, O'Callaghan CJ, Karapetis CS, Zalcberg JR, Tu D, Au HJ, et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med 2007;357:2040-8.
5. Sobrero AF, Maurel J, Fehrenbacher L, Scheithauer W, Abubakr YA, Lutz MP, et al. EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol 2008;26:2311-19.
6. Lievre A, Bachet JB, Le Corre D, Boige V, Landi B, Emile JF, et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 2006;66:3992-5.
7. Van Cutsem E, Kohne CH, Hitre E, Zaluski J, Chien CRC, Makhson A, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009;360:1408-17.
8. Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC, et al. KRAS mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008;359:1757-65.
9. Tahara M, Shirao K, Boku N, Yamaguchi K, Komatsu Y, Inaba Y, et al. Multicenter phase II study of cetuximab plus irinotecan in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin and fluoropyrimidines. Jpn J Clin Oncol 2008;38:762-9.
10. Wilke H, Glynne-Jones R, Thaler J, Adenis A, Preusser P, Aguiler EA, et al. Cetuximab plus irinotecan in heavily pretreated metastatic colorectal cancer progressing on irinotecan: MABEL Study. J Clin Oncol 2008;26:5335-43.
11. Siena S, Glynne-Jones R, Adenis A, Thaler J, Preusser P, Aguiler EA, et al. Reduced incidence of infusion-related reactions in metastatic colorectal cancer during treatment with cetuximab plus irinotecan with combined steroid and antihistamine premedication. Cancer 2010;116:1827-37.
12. Van Cutsem E. Challenges in the use of epidermal growth factor receptor inhibitors in colorectal cancer. Oncologist 2006;11:1010-7.
13. Wacker B, Nagrani T, Weinberg J, Witt K, Clark G, Cagnoni PJ. Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies. Clin Cancer Res 2007;13:3913-21.
14. Yamaguchi K, Satoh T, Watanabe T, Ishiguro M, Maruyama K, Seriu T, et al. The final report of post-marketing surveillance for cetuximab in colorectal cancer in Japan. J Clin Oncol 2011;29(suppl 4):5-90 (abstract).
15. Tsuboi M, Le Chevalier T. Interstitial lung disease in patients with non-small-cell lung cancer treated with epidermal growth factor receptor inhibitors. Med Oncol 2006;23:161-70.
16. Azuma A, Kudoh S. High prevalence of drug-induced pneumonia in Japan. Jpn Med Assoc J 2007;50:405-11.
17. Saif MW, Shah MM, Shah AR. Fluoropyrimidine-associated cardiotoxicity: revisited. Expert Opin Drug Saf 2009;8: 191-202.